Publicacions destacades

• Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors.

  Castet F; Tian TV; Macarulla T;

  Referència:

  Annals Of Oncology 2025.

• A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX.

  Álvarez-Gallego R; Macarulla T; Laquente B; Peinado P; Castet F;

  (...)

  Sanz-García E; Toledano C; Quijano Y; Vicente E; Cubillo A.

  Veure llistat complet d'autors

  Referència:

  American Journal Of Clinical Oncology-Cancer Clinical Trials 2025.

• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

  Babiker, HM; Picozzi, V; Chandana, SR; Melichar, B; Kasi, A;

  (...)

  Philip, P; Ueno, M; Van Cutsem, E; Seufferlein, T; Macarulla, T.

  Veure llistat complet d'autors

  Referència:

  Journal Of Clinical Oncology 2025.

• Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

  Macarulla, T; Ren, ZG; Chon, HJ; Park, JO; Kim, JW;

  (...)

  Liu, B; Guan, XN; Lu, S; Wang, YL; El-Khoueiry, AB.

  Veure llistat complet d'autors

  Referència:

  Journal Of Clinical Oncology 2025.

• Genomic profiling unlocks new treatment opportunities for ampullary carcinoma

  Fabregat-Franco C; Castet F; Castillo G; Salcedo M; Sierra A;

  López-Valbuena D; Pando E; Tian TV; Macarulla T.

  Referència:

  Esmo Open 2025.

• Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

  Castet F; Fabregat-Franco C; Bridgewater J; Kim JW; Rimini M;

  (...)

  Rimassa L; Casadei-Gardini A; Yoo C; Valle JW; Macarulla T.

  Veure llistat complet d'autors

  Referència:

  Journal Of Hepatology 2025.

• Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

  Melisi D; Macarulla T; De La Fouchardière C; Pazo Cid RA; Chandana SR;

  (...)

  Maxwell F; Zhang L; Benzaghou F; O'Reilly EM; Wainberg ZA.

  Veure llistat complet d'autors

  Referència:

  Esmo Open 2025.

• Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  González-Medina, A; Vila-Casadesús, M; Gomez-Rey, M; Fabregat-Franco, C; Sierra, A;

  (...)

  Miquel, JM; Nuciforo, P; Pérez-López, R; Macarulla, T; Vivancos, A.

  Veure llistat complet d'autors

  Referència:

  Clinical Cancer Research 2024.

• Facts and Hopes in the Systemic Therapy of Biliary Tract Carcinomas

  Lamarca, A; Macarulla, T;

  Referència:

  Clinical Cancer Research 2024.

• Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

  Bockorny, B; Macarulla, T; Semenisty, V; Borazanci, E; Feliu, J;

  (...)

  Ickowicz, D; Sorani, E; Kadosh, S; Vainstein-Haras, A; Hidalgo, M.

  Veure llistat complet d'autors

  Referència:

  Clinical Cancer Research 2021.